![腾博会官网·[中国]-诚信为本,专业服务!
制药英文站](http://zhengzhoujiaobanji.com/userfiles/images/banner/sinologo.png)
Investors
Information Disclosure
-
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 5 JUNE 20242024.06.05
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 20242024.06.03
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA2024.05.23
-
NEXT DAY DISCLOSURE RETURN2024.05.17
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION "BENMELSTOBART (TQB2450)" IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE INDICATION OF FIRST-LINE TREATMENT FOR SMALL CELL LUNG CANCER2024.05.09
-
IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING2024.05.07
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 20242024.05.06
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"2024.04.30